|Bid||0.00 x N/A|
|Ask||0.00 x N/A|
|Day's range||0.00 - 0.00|
|Beta (5Y monthly)||0.57|
|PE ratio (TTM)||N/A|
|Earnings date||02 May 2023 - 08 May 2023|
|Forward dividend & yield||N/A (N/A)|
|1y target est||N/A|
Ionis (IONS) reports positive long-term phase III study data, supporting the benefits of eplontersen as a treatment for hereditary transthyretin-mediated amyloid polyneuropathy (ATTRv-PN).
Ionis Pharmaceuticals (IONS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Ionis (IONS) Q4 loss is narrower than expected. However, sales miss estimates. Revenue guidance for 2023 looks soft. Stock down.